REFERENCES
Behjati, S., and Frank, M. (2009). The Effects of Tamoxifen on Immunity.
Curr. Med. Chem. 16 :3076–3080.
Bekele, R.T., Venkatraman, G., Liu, R.Z., Tang, X., Mi, S., Benesch,
M.G.K., … Brindley, D. N. (2016). Oxidative stress contributes to the
tamoxifen-induced killing of breast cancer cells: Implications for
tamoxifen therapy and resistance. Sci. Rep. 6 :21164.
Bewley, M.A., Budd, R.C., Ryan, E., Cole, J., Collini, P., Marshall, J.,
… Dockrell, D. H. (2018). Opsonic phagocytosis in chronic obstructive
pulmonary disease is enhanced by Nrf2 agonists. Am. J. Respir. Crit.
Care Med. 198 :739–750.
Bowie, M.L., Dietze, E.C., Delrow, J., Bean, G.R., Troch, M.M.,
Marjoram, R.J., and Seewaldt, V. L. (2004). Interferon-regulatory
factor-1 is critical for tamoxifen-mediated apoptosis in human mammary
epithelial cells. Oncogene 23 :8743–8755.
Butts, A., Koselny, K., Chabrier-Roselló, Y., Semighini, C.P., Brown,
J.C.S., Wang, X., … Krysan, D. J. (2014). Estrogen receptor
antagonists are anti-cryptococcal agents that directly bind EF hand
proteins and synergize with fluconazole in vivo. MBio5 :(1):e00765-13.
Clarke, R., Liu, M.C., Bouker, K.B., Gu, Z., Lee, R.Y., Zhu, Y.,
… Hilakivi-Clarke, L.A. (2003). Antiestrogen resistance in breast
cancer and the role of estrogen receptor signaling. Oncogene22 :7316–7339.
Curtis, M.J., Alexander, S., Cirino, G., Docherty, J.R., George, C.H.,
Giembycz, M.A., … Ahluwalia, A. (2018). Experimental design and
analysis and their reporting II: updated and simplified guidance for
authors and peer reviewers. Br. J. Pharmacol. 175 :987–993.
Dellê, H., Rocha, J.R.C., Cavaglieri, R.C., Vieira, J.M., Malheiros,
D.M.A.C., and Noronha, I.L. (2012). Antifibrotic effect of tamoxifen in
a model of progressive renal disease. J. Am. Soc. Nephrol.23 :37–48.
Fenaroli, F., Robertson, J.D., Scarpa, E., Gouveia, V.M., Guglielmo, C.
Di, Pace, C. De, … Rizzello, L. (2020). Polymersomes Eradicating
Intracellular Bacteria. ACS Nano 14 :8287–8298.
Feng, L., Li, J., Yang, L., Zhu, L., Huang, X., Zhang, S., … Jin, H.
(2017). Tamoxifen activates Nrf2-dependent SQSTM1 transcription to
promote endometrial hyperplasia. Theranostics 7 :1890–1900.
Fischer, J., Jung, N., Robinson, N., and Lehmann, C. (2015). Sex
differences in immune responses to infectious diseases. Infection43 :399–403.
Harvey, C.J., Thimmulappa, R.K., Sethi, S., Kong, X., Yarmus, L., Brown,
R.H., … Biswal, S. (2011). Targeting Nrf2 Signaling Improves
Bacterial Clearance by Alveolar Macrophages in Patients with COPD and in
a Mouse Model HHS Public Access. Sci Transl Med. 13 :78–110.
Hasegawa, G., Akatsuka, K., Nakashima, Y., Yokoe, Y., Higo, N., and
Shimonaka, M. (2018). Tamoxifen inhibits the proliferation of
non-melanoma skin cancer cells by increasing intracellular calcium
concentration. Int. J. Oncol. 53 :2157–2166.
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel,
J.D., and Yamamoto, M. (1999). Keap1 represses nuclear activation of
antioxidant responsive elements by Nrf2 through binding to the
amino-terminal Neh2 domain. Genes Dev. 13 :76–86.
Jaillon, S., Berthenet, K., and Garlanda, C. (2019). Sexual Dimorphism
in Innate Immunity. Clin. Rev. Allergy Immunol. 56 :308–321.
Jiang, M., Zhang, L., Chen, Y., Wang, Q., Yin, Z., Zhu, Y., … Han, J.
(2013). Tamoxifen inhibits macrophage FABP4 expression through the
combined effects of the GR and PPARγ pathways. Biochem. J 467–477.
Kilkenny, C., Browne, W., Cuthill, I., Emerson, M., and Altman, D.
(2010). Improving bioscience research reporting: The ARRIVE guidelines
for reporting animal research. J. Pharmacol. Pharmacother. 1 :94.
Kim, S.K., Yang, J.W., Kim, M.R., Roh, S.H., Kim, H.G., Lee, K.Y.,
… Kang, K. W. (2008). Increased expression of Nrf2/ARE-dependent
anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free
Radic. Biol. Med. 45 :537–546.
Kisanga, E.R., Gjerde, J., Guerrieri-Gonzaga, A., Pigatto, F.,
Pesci-Feltri, A., Robertson, C., … Lien, E. A. (2004). Tamoxifen
and Metabolite Concentrations in Serum and Breast Cancer Tissue during
Three Dose Regimens in a Randomized Preoperative Trial. Clin. Cancer
Res. 10 :2336–2343.
Klein, S.L., and Flanagan, K.L. (2016). Sex differences in immune
responses. Nat. Rev. Immunol. 16 :626–638.
Kobayashi, E.H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M.,
Sekine, H., … Yamamoto, M (2016). Nrf2 suppresses macrophage
inflammatory response by blocking proinflammatory cytokine
transcription. Nat. Commun. 7 :11624.
Koninckx, P.R., Kennedy, S.H., and Barlow, D.H. (1998). Endometriotic
disease: The role of peritoneal fluid. Hum Reprod Update.4 (5):741-51.
Kovats, S. (2015). Estrogen receptors regulate innate immune cells and
signaling pathways. Cell. Immunol. 294 :63–69.
Larsson, A.M., Roxå, A., Leandersson, K., and Bergenfelz, C. (2019).
Impact of systemic therapy on circulating leukocyte populations in
patients with metastatic breast cancer. Sci. Rep. 9 (1):13451.
Lee, Y.S., Kang, Y.S., Lee, S.H., and Kim, J.A. (2000). Role of NAD(P)H
oxidase in the tamoxifen-induced generation of reactive oxygen species
and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ.7 :925–932.
Lilley, E., Stanford, S.C., Kendall, D.E., Alexander, S.P.H., Cirino,
G., Docherty, J.R., … Ahluwalia, A. (2020). ARRIVE 2.0 and the British
Journal of Pharmacology: Updated guidance for 2020. Br. J. Pharmacol.177 :3611–3616.
Liu, L., Zou, P., Zheng, L., Linarelli, L.E., Amarell, S., Passaro, A.,
… Cheng, Z. (2015). Tamoxifen reduces fat mass by boosting
reactive oxygen species. Cell Death Dis. 6 :(1):e1586.
Lønning, P.E., Haynes, B.P., Straume, A.H., Dunbier, A., Helle, H.,
Knappskog, S., and Dowsett, M. (2011a). Exploring breast cancer estrogen
disposition: The basis for endocrine manipulation. Clin. Cancer Res.17 :4948–4958.
Lønning, P.E., Haynes, B.P., Straume, A.H., Dunbier, A., Helle, H.,
Knappskog, S., and Dowsett, M. (2011b). Recent data on intratumor
estrogens in breast cancer. Steroids 76 (8):786-91.
Ma, G., Ma, G., He, J., Yu, Y., Xu, Y., Xu, Y., … Xu, J. (2015).
Tamoxifen inhibits ER-negative breast cancer cell invasion and
metastasis by accelerating twist1 degradation. Int. J. Biol. Sci.11 :618–628.
Mantovani, A., and Locati, M. (2009). Orchestration of macrophage
polarization. Blood 114 :3135–3136.
McDonnell, D.P., and Norris, J.D. (2002). Connection and regulation of
the human estrogen receptor. Science. 296 :1642–1644.
Montoya, M.C., and Krysan, D.J. (2018). Repurposing estrogen receptor
antagonists for the treatment of infectious disease. MBio9 :(6):e02272-18.
Mornata, F., Pepe, G., Sfogliarini, C., Brunialti, E., Rovati, G.,
Locati, M., … Vegeto, E. (2020). Reciprocal interference between the
NRF2 and LPS signaling pathways on the immune-metabolic phenotype of
peritoneal macrophages. Pharmacol. Res. Perspect. 8 :(4):e00638.
Nicolao, M.C., Elissondo, M.C., Denegri, G.M., Goya, A.B., and Cumino,
A.C. (2014). In Vitro and in Vivo effects of tamoxifen against larval
stage Echinococcus granulosus. Antimicrob. Agents Chemother.58 :5146–5154.
Pepe, G., Braga, D., Renzi, T.A., Villa, A., Bolego, C., D’Avila, F.,
… Vegeto, E. (2017). Self-renewal and phenotypic conversion are
the main physiological responses of macrophages to the endogenous
estrogen surge. Sci. Rep. 7 :44270.
Pepe, G., Locati, M., Torre, S. Della, Mornata, F., Cignarella, A.,
Maggi, A., and Vegeto, E. (2018). The estrogen-macrophage interplay in
the homeostasis of the female reproductive tract. Hum. Reprod. Update24 :652–672.
Revankar, C.M., Cimino, D.F., Sklar, L.A., Arterburn, J.B., and
Prossnitz, E.R. (2005). A transmembrane intracellular estrogen receptor
mediates rapid cell signaling. Science 307 :1625–1630.
Rich, R.L., Hoth, L.R., Geoghegan, K.F., Brown, T.A., Lemotte, P.K.,
Simons, S.P., … Myszka, D. G. (2002). Kinetic analysis of estrogen
receptor/ligand interactions. Proc. Natl. Acad. Sci. U. S. A.99 :8562–8567.
Rizzi, N., Brunialti, E., Cerri, S., Cermisoni, G., Levandis, G.,
Cesari, N., … Ciana, P. (2018). In vivo imaging of early signs of
dopaminergic neuronal death in an animal model of Parkinson’s disease.
Neurobiol. Dis. 114 :74–84.
Robertson, J.D., Rizzello, L., Avila-Olias, M., Gaitzsch, J., Contini,
C., MagoÅ, M.S., … Battaglia, G. (2016). Purification of Nanoparticles
by Size and Shape. Sci. Rep. 6 :27494.
Sanghvi, V.R., Leibold, J., Mina, M., Ciriello, G., Hendrickson, R.C.,
and Correspondence, H.-G.W. (2019). The Oncogenic Action of NRF2 Depends
on De-glycation by Fructosamine-3-Kinase In Brief Fructosamine-3-kinase
promotes hepatocellular carcinoma by mediating deglycation of NRF2, a
protein modification process previously understudied for cellular
proteins. Cell 178 :807–819.
Shepherd, R., Cheung, A.S., Pang, K., Saffery, R., and Novakovic, B.
(2021). Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones
and Epigenetics. Front. Immunol. 11 :604000.
Sik Jang, W., Kim, S., Podder, B., Anirban Jyoti, M., Nam, K.-W., Lee,
B.-E., and Song, H.-Y. (2015). Anti-Mycobacterial Activity of Tamoxifen
Against Drug-Resistant and Intra-Macrophage Mycobacterium tuberculosis.
J. Microbiol. Biotechnol 25 :946–950.
Vaglio, A., Palmisano, A., Alberici, F., Maggiore, U., Ferretti, S.,
Cobelli, R., … Buzio, C. (2011). Prednisone versus tamoxifen in
patients with idiopathic retroperitoneal fibrosis: An open-label
randomised controlled trial. Lancet 378 :338–346.
Vargas-Villavicencio, J.A., Larralde, C., León-Nava, M.A. De, Escobedo,
G., and Morales-Montor, J. (2007). Tamoxifen treatment induces
protection in murine cysticercosis. J. Parasitol. 93 :1512–1517.
Vázquez-Martínez, E.R., García-Gómez, E., Camacho-Arroyo, I., and
González-Pedrajo, B. (2018). Sexual dimorphism in bacterial infections.
Biol. Sex Differ. 9 (1):27.
Vegeto, E., Cuzzocrea, S., Crisafulli, C., Mazzon, E., Sala, A., Krust,
A., and Maggi, A. (2010). Estrogen Receptor-as a Drug Target Candidate
for Preventing Lung Inflammation. Endocrinology 151 :174–184.
Vegeto, E., Villa, A., Torre, S. Della, Crippa, V., Rusmini, P.,
Cristofani, R., … Poletti, A. (2020). The Role of Sex and Sex Hormones
in Neurodegenerative Diseases. Endocr. Rev. 41 (2):273-319.
Villa, A., Rizzi, N., Vegeto, E., Ciana, P., and Maggi, A. (2015).
Estrogen accelerates the resolution of inflammation in macrophagic
cells. Sci. Rep. 5 :15224.
Wang, X., Zhao, L., Zhang, Y., Ma, W., Gonzalez, S.R., Fan, J., …
Wong, W. T. (2017a). Tamoxifen provides structural and functional rescue
in murine models of photoreceptor degeneration. J. Neurosci.37 :3294–3310.
Wang, Z., Guo, S., Wang, J., Shen, Y., Zhang, J., and Wu, Q. (2017b).
Nrf2/HO-1 mediates the neuroprotective effect of mangiferin on early
brain injury after subarachnoid hemorrhage by attenuating
mitochondria-related apoptosis and neuroinflammation. Sci. Rep.7 :(1):11883.
Weinstock, A., Gallego-Delgado, J., Gomes, C., Sherman, J., Nikain, C.,
Gonzalez, S., … Rodriguez, A. (2019). Tamoxifen activity against
Plasmodium in vitro and in mice. Malar J 18 :378.
Y. Maximov, P., M. Lee, T., and Craig Jordan, V. (2013). The Discovery
and Development of Selective Estrogen Receptor Modulators (SERMs) for
Clinical Practice. Curr. Clin. Pharmacol. 8 :135–155.
Zheng, W., Sun, W., and Simeonov, A. (2018). Drug repurposing screens
and synergistic drug-combinations for infectious diseases. Br. J.
Pharmacol. 175 :181–191.